<DOC>
	<DOCNO>NCT02614066</DOCNO>
	<brief_summary>This single arm , open-label , multi-center , phase 1/2 study , determine safety efficacy KTE-C19 , autologous anti-CD19 chimeric antigen receptor ( CAR ) -positive T cell therapy , relapsed/refractory B-precursor acute lymphoblastic leukemia ( ALL ) .</brief_summary>
	<brief_title>A Study Evaluating KTE-C19 Adult Subjects With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia ( r/r ALL ) ( ZUMA-3 )</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<criteria>1 . Relapsed refractory Bprecursor ALL define one following : Primary refractory disease First relapse first remission ≤ 12 month Relapsed refractory disease first later salvage therapy Relapsed refractory disease allogeneic transplant provide subject least 100 day stem cell transplant time enrollment 2 . Morphological disease bone marrow ( ≥ 5 % blast ) 3 . Subjects Ph+ disease eligible intolerant tyrosine kinase inhibitor ( TKI ) therapy , relapsed/refractory disease despite treatment least 2 different TKIs 4 . Age 18 old 5 . Eastern cooperative oncology group ( ECOG ) performance status 0 1 6 . Adequate renal , hepatic , pulmonary cardiac function define : Creatinine clearance ( estimate Cockcroft Gault ) ≥ 60 cc/min Serum ALT/AST ≤ 2.5 x ULN Total bilirubin ≤ 1.5 mg/dl , except subject Gilbert 's syndrome . Cardiac ejection fraction ≥ 50 % , evidence pericardial effusion , clinically significant arrhythmias Baseline oxygen saturation &gt; 92 % room air 7 . In subject previously treat blinatumomab , CD19 tumor expression bone marrow peripheral blood . 1 . Diagnosis Burkitt 's leukemia/lymphoma accord WHO classification chronic myelogenous leukemia lymphoid blast crisis 2 . History malignancy nonmelanoma skin cancer carcinoma situ ( e.g . cervix , bladder , breast ) unless disease free least 3 year 3 . Isolated extramedullary disease 4 . CNS abnormalities Presence CNS3 disease CNS2 disease neurological change History presence CNS disorder seizure disorder , cerebrovascular ischemia/hemorrhage , dementia , cerebellar disease , autoimmune disease CNS involvement 5 . History concomitant genetic syndrome Fanconi anemia , Kostmann syndrome , ShwachmanDiamond syndrome know bone marrow failure syndrome 6 . History myocardial infarction , cardiac angioplasty stenting , unstable angina , clinically significant cardiac disease within 12 month enrollment 7 . History symptomatic deep vein thrombosis pulmonary embolism within 6 month enrollment . 8 . Primary immunodeficiency 9 . Known infection HIV , hepatitis B ( HBsAg positive ) hepatitis C virus ( antiHCV positive ) . 10 . Presence fungal , bacterial , viral , infection uncontrolled require IV antimicrobial management . 11 . Prior medication : Salvage chemotherapy include TKIs Ph+ ALL within 1 week prior enrollment Prior CD19 direct therapy blinatumomab Treatment alemtuzumab within 6 month prior leukapheresis , treatment clofarabine cladribine within 3 month prior leukapheresis Donor lymphocyte infusion ( DLI ) within 28 day prior enrollment Any drug use GVHD within 4 week prior enrollment At least 3 halflives must elapse prior systemic inhibitory/stimulatory immune checkpoint molecule therapy prior enrollment Corticosteroid therapy 7 day prior enrollment 12 . Presence indwell line drain ( e.g. , percutaneous nephrostomy tube , indwell Foley catheter , biliary drain , pleural/peritoneal/pericardial catheter ) . Ommaya reservoirs dedicated central venous access catheter PortaCath Hickman catheter permit 13 . Acute GVHD grade IIIV Glucksberg criterion severity BD IBMTR index ; acute chronic GVHD require systemic treatment within 4 week prior enrollment 14 . Live vaccine ≤ 4 week prior enrollment 15 . Women childbearing potential pregnant breastfeed potentially dangerous effect preparative chemotherapy fetus infant . Females undergone surgical sterilization postmenopausal least 2 year consider childbearing potential 16 . Subjects gender childbearing potential willing practice birth control time consent 6 month completion KTEC19 17 . In investigator judgment , subject unlikely complete protocolrequired study visit procedure , include followup visit , comply study requirement participation 18 . History autoimmune disease ( e.g . Crohns , rheumatoid arthritis , systemic lupus ) result end organ injury require systemic immunosuppression/systemic disease modify agent within last 2 year</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>